

APPLICATION FOR BYPRODUCT MATERIAL LICENSE
SUPPLEMENT A—HUMAN USE

Form approved
Budget Bureau No. 58-2093

The data may be completed by the physician's precursor (if any) in the lawful use of radioisotopes. When the information is not furnished by the precursor, the name and present address of the precursor (if any) should be shown in Item 12 below.

1) USING PRECURSOR'S NAME
JOSEPH T. MAHER, Capt, MC

2) NAME AND ADDRESS OF APPLICANT (if different from 1(a))

10. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN WHO WILL USE BYPRODUCT MATERIAL

(A) ISOTOPE	CONDITIONS, DIAGNOSED OR TREATED	NUMBER OF CASES	TYPE OF PARTICIPATION (SEE ALL CASES IN COLUMN 10)				
			1	2	3	4	
I-131	Diagnosis of thyroid function	289			(3)	(4)	
	Treatment of hyperthyroidism				(3)	(4)	
	Treatment of thyroid cancer		15			(3)	(4)
	Treatment of cardiac conditions		5			(3)	(4)
	Breast tumor localization		2			(3)	(4)
	Blood determinations		3			(3)	(4)
P-32 Soluble	Others: Radioactive Renal Scan	5			(3)	(4)	
	Radioactive Liver Scan	8			(3)	(4)	
	Treatment of polycythemia and leukemias	1			(3)	(4)	
P-32 Colloid	Breast tumor localization	10			(3)	(4)	
	Treatment of bone metastases				1	2	
	Others:				1	2	
Co-60	Treatment of prostatic cancer				1	2	
	Treatment of cervical cancer				1	2	
	Treatment of pleural effusions and/or ascites				1	2	
Au-195 Colloid	Others:	3			(1)	(2)	
	Treatment of prostatic cancer				1	2	
	Treatment of cervical cancer				1	2	
Cr-51	Treatment of pleural effusions and/or ascites				1	2	
	Others:	9			(3)	(3)	
	Blood determinations				1	2	
Other Isotopes	Others:	33			(1)	(2)	
	Gd-67 Scintillation Test for Pernicious Anemia				1	2	
	Pb-212 In vivo Absorption Study	12			(3)	(2)	
	H-3 Total Body Water Study	8			(3)	(2)	
		6			(4)	(2)	

- Key to above numbers (columns D)
1. Exemption of patient to determine suitability for radioisotope diagnosis and/or treatment and measurement of uptake or change to be measured.
 2. Participation in collection and administration of dosage including patient preparation and timing of dose.
 3. Active period of handling and experience of subject's condition to permit delivery of isotope through instrument and measurement period including observation as to effectiveness and complications.
 4. Study, read discussion of case history including all pertinent diagnosis and/or treatment, laboratory and/or clinical data.

11. TOTAL NUMBER OF HOURS OF PARTICIPATION IN CLINICAL TRAINING: **160**

12. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF: **Walter Reed Army Institute of Research**
JOHN G. MAHER, Capt, MC Chief, Radioisotopes Clinic
Washington 12, D. C.
John G. Maher

Incl 2

ARM2.950113.001H

Washington National Record Center
Office of the Army Surgeon General
Record Group 112
Accession #: 68A 3359
Box #: 47/75
File: 901-03 OTSG Radioisotope Committee '64